Accession Number: | 0001209191-21-008802 |
Date: | 2021-02-05 |
Issuer: | TRAVERE THERAPEUTICS, INC. (TVTX) |
Original Submission Date: |
CLAGUE LAURA
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
SAN DIEGO, CA 92130
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-02-05 | S | 2,250 | d | $31.41 | 34,473 | direct | ||
COMMON STOCK | 2021-02-08 | S | 2,250 | d | $31.58 | 32,223 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on february 5, 2021. |